|Application ||WB, IHC-P, E|
|Calculated MW||84419 Da|
|Antigen Region||342-371 aa|
|Other Names||Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX32, DEAD/H box 32, DEAD/H helicase-like protein 1, DHLP1, DEAH box protein 32, HuDDX32, DHX32, DDX32|
|Target/Specificity||This DHX32 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 342-371 amino acids from the Central region of human DHX32.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||DHX32 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Nucleus. Mitochondrion|
|Tissue Location||Expressed in lymphoid tissues (at protein level). Expressed in brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung, lymphoid tissues and blood leukocytes.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. Based on their distribution patterns, some members of this DEAD box protein family are believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. This gene encodes a member of this family. The function of this member has not been determined. Alternative splicing of this gene generates 2 transcript variants, but the full length nature of one of the variants has not been defined.
Huang, C., et al. J. Exp. Clin. Cancer Res. 28, 11 (2009) :
Chen, Y., et al. Exp. Mol. Pathol. 82(3):256-261(2007)
Alli, Z., et al. Anticancer Res. 27 (1A), 373-377 (2007) :
Alli, Z., et al. Exp. Mol. Pathol. 81(3):245-248(2006)
Alli, Z., et al. Cell. Immunol. 237(2):141-146(2005)
If you have any additional inquiries please email technical services at email@example.com.